Tuesday, March 28, 2017

ASH 2016: Dr. Matt Davids of the combination of TGR-1202 and ibrutinib for relapsed refractory CLL (chronic lymphocytic leukemia)

This week, on the CLL Society website we are sharing a video interview with Dr. Matthew Davids from  ASH 2016 where we discuss a clinical trial that combines two targeted therapies for treating relapsed/refractory CLL, ibrutinib and TGR-1202. You can read the summary and watch the video or read the transcript here .

TOMORROW, we'll be publishing the first 2017 issue of The CLL Tribune and marking the 2 year anniversary since our website went live! Watch for it!

Two years. WOW!
CLL Patient Support Group Meetings This Week

Monday, April 3rd at 6 PM in Indianapolis - the CLL and Indolent Blood Cancers Support Group will be meeting. More information here.

Tuesday, April 4th at 7 PM in Tucker, GA - the Tucker Family Support Group, sponsored by the Leukemia and Lymphoma Society will be meeting.  More information here.  
 
NEW CLL Patient Support Group Meetings Coming Up

Saturday, April 15th at 3 PM in Vienna, VA - 
the Washington DC-Area CLL Support Group, sponsored by the CLL Society will be meeting for the first time. More information here.

Saturday, April 22nd at 1 PM in the Boston area -
the Boston CLL Support Group, sponsored by the CLL Society will be meeting for the first time. More information here

Sunday, April 23rd at 4 PM in San Francisco - 
the San Francisco CLL Support Group, sponsored by the CLL Society will be meeting for the first time. More information here

ALSO - 
We are actively forming CLL-specific support group in a number of cities around the country. To see if your city is one of them, go to our home page  and click on the interest survey for your city. JUST ADDED - Rochester, NY; Milwaukee, WI; Atlanta, GA; Salt Lake City, UT; Huntsville, AL. Not listed, but interested in starting one? Email us at support@cllsociety.orgThanks!

Upcoming Patient Education Meetings
  • Saturday, April 1st from 7:30 AM to 3:00 PM in Atlanta, GA: The Lymphoma Research Foundation will be hosting Lymphoma Workshop: Understanding Lymphoma Basics and Current Treatment Options which will include disease-specific breakout sessions. There is no cost to attend, but registration is required. Find out more information here. ALSO Rick Conner, a CLL patient in the Atlanta area will be manning the CLL Society table and collecting names of those who might be interested in a CLL-specific patient support group. Stop by and say Hello!
  • Thursday, April 6th from 6:00 PM to 8:30 PM in Boston, MA: The Lymphoma Research Foundation will be hosting Ask the Doctor: Updates on CLL/SLL. There is no cost to attend, but registration is required. Dinner will be provided for registered attendees. Find out more information here. 
  • Thursday, April 20th from 6:00 PM to 8:30 PM in Cherry Hill, NJ: Anthony Mato, MD, MSCE from the Abramson Cancer Center in Philadelphia will be chairing the patient educational forum, CLL in 2017: State of the Art Management from a Patient's Perspective with his team. Brian Koffman, MD from the CLL Society will also be speaking. There is no cost to attend, but registration is required. Attendance is limited and registration will be closed when attendance limits are reached. Dinner will be provided for registered attendees. Find out more information here. 
  • Monday, April 24th in Columbus, OH and streaming live: Ask the Expert: Nutrition & Chronic Lymphocytic Leukemia will be held at The James at Ohio State University. This event is free, but pre-registration is required. Visit https://nutritionandcll.eventbrite.com  to register or for more information, please call JamesCare for Life at 614-293-6428. Find out more information here
In the meantime....

Stay strong.

We are all in this together.

Brian Koffman, MD
March 28, 2017


Labels: , , , , , ,

Wednesday, March 22, 2017

Combination Therapy in CLL

This week, I am sharing a video of Dr. Jennifer Brown from Dana Farber Cancer Institute where she discusses the possible next steps in combination treatment strategies for chronic lymphocytic leukemia (CLL). You can read my summary and watch the interview here.

This is the future. And the direction that we need to continue to research

NEXT WEEK, we'll be publishing the first 2017 issue of The CLL Tribune and marking the 2 year anniversary since our website went live! Stay tuned!

Stay strong.

We are all in this together.

Brian

http://cllsociety.org

Labels: , , ,

Saturday, March 11, 2017

Test Before Treat: The importance of genetic testing in CLL

It is critical not just to get the diagnosis of our blood cancer right which may be wrong up to 20%, but also to know the genetic make-up of our cancer. Knowing that can determine what treatment will work and which won't. Genetic testing is so important in CLL. This short TV interview with Dr. Pau Barr is surprisingly sharp and informative.

Here is a link to the interview:

http://foxrochester.com/…/closer-look-at-genetic-testing-fo…

Labels: , ,

Monday, February 20, 2017

Dr, Jeff Jones on the importance of genetic Testing Before Treating our CLL (chronic lymphocytic leukemia) or any cancer

In this short but pithy news interview, Dr. Jeff Jones from Ohio State explains why it so very important to know the details of your cancer before starting on any treatment.

It could be a matter of life or death,

Please enjoy this brief and helpful interview:

Labels: , , ,

Wednesday, February 15, 2017

Reflecting on the three Year Anniversary of the Approval of Ibrutinib in the USA

I realized this week that Feb. 12 was the 3rd anniversary of the approval of ibrutinib in the USA that changed the whole treatment landscape in CLL, so I thought I would reflect on all the progress that has taken place in the treatment of our disease during this time frame and all the issues that still remain. You can read my thoughts and share your own here: http://cllsociety.org/2017/02/reflections-three-year-anniversary/

What a wild and wonderful three years it has been- but we are not over the finish line quite yet.

Stay strong.

We are all in this together.

Brian

http://cllsociety.org

Labels: , ,

Sunday, February 12, 2017

How Ibrutinib and other perhaps other BTK inhibitor work over time in CLL (chronic lymphocytic leukemia)

At ASH 2016 in San Diego, CA, I had the honor of once again interviewing Dr. Wiestner from the NIH (National Institute of Health) about the prototype BTK inhibitor, ibrutinib and how and why it works so well in CLL.

We have known for a while that for its survival and well-being, our cancer is dependent on BCR (B cell receptor) signaling. Blocking BTK (Bruton’s Tyrosine Kinase), blocks that BCR signaling and that blocking usually leads to our cancer’s retreat.

This is a well-understood critical tenet of why ibrutinib works as well as it does, but it is hardly the whole story as we are learning over time.

At the NIH, Dr. Wiestner and his team not only did some of the earliest clinical research on ibrutinib, but also has been doing the bench science on exactly how it works and its impact changes over time.

Please enjoy the interview here: http://cllsociety.org/2017/02/ash-2016-wiestner-ibrutinib-cll/

Stay strong.

We are all in this together.

Brian

http://cllsociety.org

Labels: , , , , , ,

Thursday, February 9, 2017

Healthevoices Health Advocacy Conference 2017

I have attended a meeting sponsored by Janssen on online health advocacy the last two years and hope to be returning again this April 21-23. It is a strong meeting, full of good info, much fun and great folks. I highly recommend it and alway learn from it. It is more for individuals than organizations.
Patients and caregivers with HIV, colitis, psoriasis, schizophrenia, different cancers and many more conditions attend. 
I was asked to reach out to friends who have an online advocacy presence in the cancer world to see if they are interested in attending. The deadline has been extended to Feb 13. To apply and learn more, please go to: https://www.healthevoices.com

Labels: